Angiotensin II and abdominal aortic aneurysms: An update

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations

Abstract

Abdominal aortic aneurysm (AAA) is a devastating disease associated with high prevalence of death due to aortic rupture. Currently the therapy is restricted to surgical procedures to prevent aortic rupture, which in turn has a risk for postoperative mortality. There are no proven pharmacological therapies available to prevent expansion or rupture of AAA due to the paucity of knowledge on the mechanisms underlying the nature and pathophysiological processes of this complex disease. Animal models are powerful tools to provide mechanistic insights into understanding the development of AAA. Numerous pharmacological approaches have been explored as potential therapies in experimental AAA in the past decade. This review overviews recent advances in mechanistic studies of AAA in angiotensin II-infused mouse models and highlights their clinical relevance for possible therapeutic targets.

Original languageEnglish
Pages (from-to)4035-4048
Number of pages14
JournalCurrent Pharmaceutical Design
Volume21
Issue number28
DOIs
StatePublished - Oct 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Bentham Science Publishers.

Keywords

  • Abdominal aortic aneurysms
  • Angiotensin
  • Inflammation
  • Mechanisms
  • Mouse

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Angiotensin II and abdominal aortic aneurysms: An update'. Together they form a unique fingerprint.

Cite this